Comparative Pharmacology
Head-to-head clinical analysis: EQUETRO versus OXCARBAZEPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUETRO versus OXCARBAZEPINE.
EQUETRO vs OXCARBAZEPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Equetro (carbamazepine extended-release) is an anticonvulsant and mood stabilizer. It stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission. It also potentiates GABA receptors and inhibits glutamate release.
Stabilization of neuronal membranes by blockade of voltage-sensitive sodium channels, leading to inhibition of repetitive firing and reduction of neurotransmitter release.
Initial: 50 mg orally twice daily; increase by 50-100 mg/day every 2-4 weeks. Usual maintenance: 100-200 mg orally twice daily. Maximum: 200 mg orally twice daily.
Initial 300 mg orally twice daily; increase by 300 mg/day every third day to target dose of 600-1200 mg/day in two divided doses. Maximum 2400 mg/day.
None Documented
None Documented
Clinical Note
moderateOxcarbazepine + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Cobicistat
"The serum concentration of Cobicistat can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Oxcarbazepine."
Clinical Note
moderateOxcarbazepine + Saxagliptin
Carbamazepine: 25-65 hours (initial single dose), 12-17 hours (chronic dosing due to autoinduction); carbamazepine-10,11-epoxide: 5-8 hours.
Oxcarbazepine: 2 hours (parent drug); MHD (active metabolite): 9 hours. Steady-state achieved in 2-3 days. Context: shorter t1/2 than carbamazepine; MHD t1/2 extended in renal impairment (up to 19 hours).
Renal: 2% excreted unchanged (carbamazepine) in urine; 15% as carbamazepine-10,11-epoxide; 30% as other metabolites; biliary/fecal: 50-60% as metabolites.
Renal: 70% (mainly as glucuronide metabolites, unchanged drug <1%). Fecal: negligible.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The serum concentration of Saxagliptin can be decreased when it is combined with Oxcarbazepine."